Retraction Note: Nuclear factor of activated T cells 5 maintained by Hotair suppression of miR-568 upregulates S100 calcium binding protein A4 to promote breast cancer metastasis [Breast Cancer Res., 16, (2014) (454)] DOI: 10.1186/s13058-014-0454-2;Nuclear factor of activated T cells 5 maintained by Hotair suppression of miR-568 upregulates S100 calcium binding protein A4 to promote breast cancer metastasis

Breast Cancer Research

Volumn 16, Issue 1, 2014, Pages

  Li, Jun Tang ^a,b   Wang, Li Feng ^a   Zhao, Ya Li ^b   Yang, Tao ^a   Li, Wei ^a   Zhao, Jing ^a   Yu, Feng ^b   Wang, Lei ^a   Meng, Yan Ling ^a   Liu, Ning Ning ^b   Zhu, Xiao Shan ^b   Gao, Chun Fang ^b   Jia, Lin Tao ^a   Yang, An Gang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b No 150 Central Hospital of PLA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CALVASCULIN; HISTONE; HISTONE H3K27; LONG UNTRANSLATED RNA; MICRORNA; MICRORNA 568; POLYCOMB REPRESSIVE COMPLEX 2; RNA HOTAIR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR LSD1; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFAT5; UNCLASSIFIED DRUG; VASCULOTROPIN C; HOTAIR LONG UNTRANSLATED RNA, HUMAN; MIRN568 MICRORNA, HUMAN; NFAT5 PROTEIN, HUMAN; PROTEIN S 100; S100A4 PROTEIN, HUMAN; VEGFC PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOGENESIS; BREAST EPITHELIUM CELL; CANCER GROWTH; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME REPRESSION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HISTONE DEMETHYLATION; HISTONE METHYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF QUANTITATION; METASTATIC BREAST CANCER; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TUMOR INVASION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BINDING SITE; BREAST TUMOR; CANCER TRANSPLANTATION; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; LYMPH NODE METASTASIS; METABOLISM; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; RNA INTERFERENCE; SECONDARY; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; BASE SEQUENCE; BINDING SITES; BREAST NEOPLASMS; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NEOPLASM TRANSPLANTATION; RNA INTERFERENCE; RNA, LONG NONCODING; S100 PROTEINS; TRANSCRIPTION FACTORS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84988811090     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-018-1021-z     Document Type: Erratum

References (37)

1. Lorusso G, Rüegg C: New insights into the mechanisms of organ-specific breast cancer metastasis. Semin Cancer Biol 2012, 22:226-233
2. Chaffer CL, Weinberg RA: A perspective on cancer cell metastasis. Science 2011, 331:1559-1564
3. Gupta GP, Massagué J: Cancer metastasis: building a framework. Cell 2006, 127:679-695
4. Nguyen DX, Bos PD, Massagué J: Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009, 9:274-284
5. Psaila B, Lyden D: The metastatic niche: adapting the foreign soil. Nat Rev Cancer 2009, 9:285-293
6. Valastyan S, Weinberg RA: Tumor metastasis: molecular insights and evolving paradigms. Cell 2011, 147:275-292
7. Jauliac S, López-Rodriguez C, Shaw LM, Brown LF, Rao A, Toker A: The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat Cell Biol 2002, 4:540-544
8. Mancini M, Toker A: NFAT proteins: emerging roles in cancer progression. Nat Rev Cancer 2009, 9:810-820
9. Müller MR, Rao A: NFAT, immunity and cancer: a transcription factor comes of age. Nat Rev Immunol 2010, 10:645-656
10. Germann S, Gratadou L, Zonta E, Dardenne E, Gaudineau B, Fougère M, Samaan S, Dutertre M, Jauliac S, Auboeuf D: Dual role of the ddx5/ddx17 RNA helicases in the control of the pro-migratory NFAT5 transcription factor. Oncogene 2012, 31:4536-4549
11. Mishra SK, Siddique HR, Saleem M: S100A4 calcium-binding protein is key player in tumor progression and metastasis: preclinical and clinical evidence. Cancer Metastasis Rev 2012, 31:163-172
12. Su JL, Yen CJ, Chen PS, Chuang SE, Hong CC, Kuo IH, Chen HY, Hung MC, Kuo ML: The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer 2007, 96:541-545
13. Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, Shi Y, Segal E, Chang HY: Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010, 329:689-693
14. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, Brzoska P, Kong B, Li R, West RB, van de Vijver MJ, Sukumar S, Chang HY: Long non-coding RNA Hotair reprograms chromatin state to promote cancer metastasis. Nature 2010, 464:1071-1076
15. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, Goodnough LH, Helms JA, Farnham PJ, Segal E, Chang HY: Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 2007, 129:1311-1323
16. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA: MicroRNAs-the micro steering wheel of tumour metastases. Nat Rev Cancer 2009, 9:293-302
17. Zhang H, Li Y, Lai M: The microRNA network and tumor metastasis. Oncogene 2010, 29:937-948
18. Frank SR, Schroeder M, Fernandez P, Taubert S, Amati B: Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev 2001, 15:2069-2082
19. Zhao Y, Tan YZ, Zhou LF, Wang HJ, Mao Y: Morphological observation and in vitro angiogenesis assay of endothelial cells isolated from human cerebral cavernous malformations. Stroke 2007, 38:1313-1319
20. Chen M, Sinha M, Luxon BA, Bresnick AR, O'Connor KL: Integrin alpha6beta4 controls the expression of genes associated with cell motility, invasion, and metastasis, including S100A4/metastasin. J Biol Chem 2009, 284:1484-1494
21. Wiig H, Schröder A, Neuhofer W, Jantsch J, Kopp C, Karlsen TV, Boschmann M, Goss J, Bry M, Rakova N, Dahlmann A, Brenner S, Tenstad O, Nurmi H, Mervaala E, Wagner H, Beck FX, Müller DN, Kerjaschki D, Luft FC, Harrison DG, Alitalo K, Titze J: Immune cells control skin lymphatic electrolyte homeostasis and blood pressure. J Clin Invest 2013, 123:2803-2815
22. Polyak K, Weinberg RA: Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009, 9:265-273
23. Li W, Kong LB, Li JT, Guo ZY, Xue Q, Yang T, Meng YL, Jin BQ, Wen WH, Yang AG: MiR-568 inhibits the activation and function of CD4+ T cells and Treg cells by targeting NFAT5. Int Immunol 2014, 26:269-281
24. Buxadé M, Lunazzi G, Minguillón J, Iborra S, Berga-Bolaños R, Del Val M, Aramburu J, López-Rodríguez C: Gene expression induced by Toll-like receptors in macrophages requires the transcription factor NFAT5. J Exp Med 2012, 209:379-393
25. Machnik A, Neuhofer W, Jantsch J, Dahlmann A, Tammela T, Machura K, Park JK, Beck FX, Müller DN, Derer W, Goss J, Ziomber A, Dietsch P, Wagner H, van Rooijen N, Kurtz A, Hilgers KF, Alitalo K, Eckardt KU, Luft FC, Kerjaschki D, Titze J: Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat Med 2009, 15:545-552
26. Roth I, Leroy V, Kwon HM, Martin PY, Féraille E, Hasler U: Osmoprotective transcription factor NFAT5/TonEBP modulates nuclear factor-kappaB activity. Mol Biol Cell 2010, 21:3459-3474
27. Feng LZ, Zheng XY, Zhou LX, Fu B, Yu YW, Lu SC, Cao NS: Correlation between expression of S100A4 and VEGF-C, and lymph node metastasis and prognosis in gastric carcinoma. J Int Med Res 2011, 39:1333-1343
28. Wang L, Wang J: MicroRNA-mediated breast cancer metastasis: from primary site to distant organs. Oncogene 2012, 31:2499-2511
29. Chen YQ, Wang XX, Yao XM, Zhang DL, Yang XF, Tian SF, Wang NS: Abated microRNA-195 expression protected mesangial cells from apoptosis in early diabetic renal injury in mice. J Nephrol 2012, 25:566-576
30. Leidner RS, Li L, Thompson CL: Dampening enthusiasm for circulating microRNA in breast cancer. PLoS One 2013, 8:e57841
31. Garcia-Closas M, Chanock S: Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res 2008, 14:8000-8009
32. Harari D, Yarden Y: Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000, 19:6102-6114
33. Tamimi RM, Colditz GA, Hazra A, Baer HJ, Hankinson SE, Rosner B, Marotti J, Connolly JL, Schnitt SJ, Collins LC: Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat 2012, 131:159-167
34. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L: Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2011, 9:16-32
35. Jordan VC, O'Malley BW: Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 2007, 25:5815-5824
36. Pal SK, Childs BH, Pegram M: Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 2011, 125:627-636
37. Scheel C, Weinberg RA: Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol 2012, 22:396-403